Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Shares are trading flat year to date and the stock remains solidly in value territory, even in the absence of near-term drivers. Clinical trial collaborations with Merck and Bristol-Myers Squibb bode ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

Shares of Array Biopharma Inc ARRY, a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a ...

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of ...

Welcome to the Array BioPharma Conference Call. My name is Don and I will be the operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a ...

* Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - ‍FDA set a target action ...

Ambrosia Biosciences has launched with a $16 million series A financing round led by BVF Partners and Boulder Ventures. Ambrosia researchers are developing small-molecule, GLP-1–based drugs for ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...